



ASX & MEDIA RELEASE

22 FEBRUARY 2017

GOVERNMENT EASING OF CANNABIS SUPPLY COMES AS MEDLAB TRIAL NEARS

As medical life science company, Medlab Clinical Limited (ASX: MDC), completes final steps to start Australia's first clinical trial using cannabis for oncology patients suffering intractable pain, the federal government has announced it intends to deliver faster supply of medicinal cannabis products.

Medlab supports this initiative and also shares medical community concerns around safeguards and evidence based prescribing of cannabis products.

In recent months, Medlab has achieved the following in the lead up to its clinical trial:

- It has obtained clearances from Australian health departments and is awaiting a final shipment clearance from Canadian health authorities, expected soon, to import cannabis material from Canada
- The cannabis material is a combination of the two most active cannabis ingredients, formulated by Medlab and being supplied by Canadian licenced producer of medical marijuana, Aphria Inc.
- Medlab has arranged delivery of the cannabis material to a contractor in Melbourne, licenced for controlled substance manufacture
- The cannabis material will be incorporated with Medlab's small particle medicine delivery system, Nanocelle™, to be readied for the trial
- In conjunction with the manufacturer, Medlab has established a drug manufacturing method that will be the prescribed template for future production

Prerequisites for trial commencement are ethics approval from Royal North Shore Hospital, which Medlab believes is progressing well, and issue of a clinical trial number from Therapeutic Goods Administration.

Medlab managing director, Mr Sean Hall, said the supportive government attitude towards cannabis was encouraging for the future prospects of Medlab's initiative with cannabis.

Establishment of a production method will allow, after completion of a successful clinical trial, commercial production, subject to approval from Therapeutic Goods Administration

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based biotechnology company, with a certified biologics facility in Sydney and sales arms in Australia and California (Medlab Clinical US Ltd, formerly InMed Technologies). Medlab's research focus is on the role bacteria in the gastrointestinal tract play in health and disease, in five health areas: obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. Medlab develops and sells nutraceuticals in the US and Australia to support drug discovery and development of new medicines involving bacteria (pharmacobiotics). Medlab has a growing patent portfolio, multiple published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.